Vaccines, Volume 8, Issue 3
2020 September - 216 articles
Cover Story: Zika virus (ZIKV) is the etiological agent responsible for a range of debilitating and often lifelong birth defects collectively termed congenital Zika syndrome (CZS). Although the ZIKV pandemic has subsided, ZIKV continues to be a burden, with 87 countries and territories now displaying autochthonous ZIKV transmission and no commercial vaccine is currently available. This paper uses a recently designed flavivirus chimeric platform comprising the backbone of an Australian mosquito virus, Binjari virus, to generate a ZIKV vaccine candidate named BinJ/ZIKV-prME. This vaccine, administered unadjuvanted and as a single dose, protected against fetal ZIKV infection and did not cause antibody-dependent enhancement of dengue infection and disease in mice. BinJ/ZIKA-prME thus emerges as a potential vaccine candidate for the prevention of CSZ. View this paper.
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Articles
There are no articles in this issue yet.
Vaccines - ISSN 2076-393X